home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


David Hirsh



Nicola Murnaghan

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
In Brief

Eye of the Storm

Emile Bellott comments on the growing prominence of biosimilars, which are currently gaining visibility at the highest government levels, and some of the challenges this presents.
Biodevelopment and Manufacturing
Supply Chain Agility

Quick on the Draw

Agility – within all stages of pharma manufacturing – is key to achieving success in company goals, believes Mark Evenepoel at AMPLEXOR Life Sciences.
  Science and Innovation
Automation Advances

Rise of the Machines

Recent advances in cognitive computing could drastically shake up the industry, states IBM's Institute for Business Value’s Heather Fraser, enabling fast and more accurate decisionmaking by healthcare professionals to enhance patient care.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

Banner of CMCBio on Samedan

Industry Events

6th Clinical Trials Innovation Programme

28-29 July 2016, Miami, Florida

The Clinical Trials Innovation Programme (CTIP) 2016 is an exclusive, invitation only event and each year helps senior executives from Pharma & Biotech industries to forge strong and lasting business relationships to share best practice and knowledge about the very latest issues affecting the industry.
More info >>

News and Press Releases

Gerresheimer is at FCE Pharma 2016 with new ‘green’ products and enhanced convenience features

Gerresheimer is presenting two new products in its range at this year’s FCE Pharma in Sao Paulo, Brazil from May 10 to 12: Biopack and Duma Combi. Biopack is a more eco-friendly alternative to PE and PET. Duma Combi is a tablet packaging with an additional compartment for the patient information sheet.
More info >>

air transport logo


White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement